BNBX · Bnb Plus Corp.
$0.13
+0.00 (+0.00%)
At close · Aug 7
Market Cap
$935,639
Shares
7.20M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.14M
+1.1%
FY2025
Net Income
-$15.16M
-116.8%
FY2025
Gross Margin
39.26%
-6.9pp
FY2025
Operating Margin
-750.92%
-104.2pp
FY2025
Diluted EPS
-$134.23
+90.2%
FY2025
Operating Cash Flow
-$12.24M
+10.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.09M | $2.14M | $2.11M | $13.37M | $18.17M | $9.03M | $1.93M | $5.39M | $3.9M | $4.75M | $4.19M | $9.01M | $2.72M | $2.04M | $1.85M | $968.85K | $519.84K | |
| $74.04K | $192.92K | $176.3K | $75.33K | $7200 | $13.68K | -$115.83K | -$162.43K | -$9615 | $2763 | $11K | -$23.47K | -$11.03K | $1272 | -$643.06K | — | — | |
| $1.11M | $1.3M | $1.14M | $7.83M | $13.12M | $4.54M | $720.9K | $877.61K | $1.21M | $1.08M | $1.17M | $384.27K | — | — | — | — | — | |
| $979.29K | $838.91K | $974.84K | $5.53M | $5.05M | $4.48M | — | — | — | — | — | — | — | — | — | — | — | |
| — | 39.26% | 46.12% | 41.39% | 27.82% | 49.66% | — | — | — | — | — | — | — | — | — | — | — | |
| $4.98M | $6.02M | $3.59M | $3.74M | $3.93M | $4.16M | $3.32M | $2.97M | $2.75M | $2.28M | $3.7M | $2.58M | $1.3M | $692.48K | $432.67K | $268.88K | $75.96K | |
| $21.32M | $10.87M | $11.05M | $12.75M | $15.1M | $12.85M | $10.03M | $10.28M | $11.04M | $13.32M | $10.81M | $13.41M | $13.25M | $11.2M | $7.62M | $8.39M | $7.19M | |
| — | — | — | — | $0 | $68.98K | $129.44K | $129.43K | $177.87K | $483.82K | $254.28K | $96.89K | $92.8K | $163.4K | $272.84K | $363.79K | — | |
| — | $384.17K | $432.6K | $1.36M | $1.29M | $844.44K | $285.73K | $390.42K | $547.8K | $633.33K | $706.5K | $490.64K | $442.26K | $206.34K | $313.94K | $367.56K | $371.91K | |
| $36.13M | $16.89M | $14.64M | $16.49M | $19.02M | $17.83M | $13.64M | $13.64M | $14.34M | $16.49M | $15.22M | $16.48M | $14.99M | $12.21M | $8.36M | $9.03M | $7.64M | |
| -$35.15M | -$16.05M | -$13.67M | -$10.95M | -$13.97M | -$13.35M | -$12.53M | -$9.12M | -$11.65M | -$12.82M | -$12.2M | -$7.85M | -$12.27M | -$10.18M | -$6.51M | -$8.06M | -$7.12M | |
| — | -750.92% | -646.72% | -81.94% | -76.89% | -147.86% | -648.98% | -169.31% | -298.37% | -269.83% | -291.41% | -87.18% | -450.96% | -499.74% | -350.87% | -831.55% | -1369.07% | |
| — | -$15.66M | -$13.24M | -$9.59M | -$12.68M | -$12.5M | -$12.25M | -$8.73M | -$11.1M | -$12.19M | -$11.49M | -$7.36M | -$11.83M | -$9.97M | -$6.19M | -$7.69M | -$6.75M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | -$1272 | $643.06K | $2.46M | $792.55K | |
| $77.33K | $192.92K | $120.48K | $75.33K | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $90.92K | -$106.58K | -$8877 | $642 | -$47.31K | -$8756 | -$378.08K | -$43.3K | -$37.01K | -$38.39K | $12.88K | -$28.31K | $123.91K | -$3761 | — | — | — | |
| -$34.97M | -$15.64M | -$6.79M | -$10.02M | -$8.27M | -$14.28M | -$13.03M | -$8.62M | -$11.69M | -$12.86M | -$12.18M | -$11.88M | -$13.07M | -$17.69M | -$7.15M | -$10.52M | -$7.91M | |
| — | -$684.12K | $0 | $0 | $0 | $0 | $0 | $15K | $0 | $0 | $0 | — | — | — | — | — | — | |
| -$6.67M | -$15.16M | -$6.99M | -$9.95M | -$8.27M | -$14.29M | -$13.03M | -$8.62M | -$11.69M | -$12.86M | -$12.18M | -$11.88M | -$13.07M | -$17.69M | -$7.15M | -$10.52M | -$7.91M | |
| — | -709.46% | -330.85% | -74.41% | -45.51% | -158.25% | -674.46% | -160.01% | -299.56% | -270.58% | -290.84% | -131.89% | -480.18% | -868.59% | -385.55% | -1085.32% | -1521.53% | |
| -$139.83K | -$188.52K | -$95.79K | -$75.86K | -$2168 | $8003 | -$1685 | -$9323 | $0 | — | — | — | — | — | — | — | — | |
| -$50.01M | -$69.49M | -$7.23M | -$9.95M | -$8.38M | -$14.29M | -$13.03M | -$8.93M | -$11.69M | — | — | — | — | — | -$7.15M | -$10.52M | — | |
| USD/shares | — | -$134.23 | -$1,366.42 | -$11,407.50 | -$13,950.00 | -$31,050.00 | -$49,800.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | — | -$134.23 | -$1,366.42 | -$11,407.50 | -$13,950.00 | -$31,050.00 | -$49,800.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 517.67K | 5288 | 871.6947 | 597.8469 | 461.1333 | 261.2715 | 61.4539 | 49.1627 | 1758.5994 | 1579.5397 | 1262.5522 | 901.0345 | 782.0586 | 38.41K | 25.12K | — |
| shares | — | 517.67K | 5288 | 871.6947 | 597.8469 | 461.1333 | 261.2715 | 61.4539 | 49.1627 | 1758.5994 | 1579.5397 | 1262.5522 | 901.0345 | 55.97K | 46.16K | 25.12K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
0.00×
Asset Management median 15.24×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | $1,148,817 | $1,218,136 | — | — | — |
| Therapeutic DNA Production | $988,118 | $895,354 | — | — | — |
| DNA Tagging and Security Products | — | $1,218,136 | $1,148,766 | $1,574,301 | $1,730,568 |
| Mdx Testing Services | — | $1,317,930 | $11,152,392 | $16,155,021 | $6,737,851 |
| Therapeutic DNA Production | — | $895,354 | $1,066,285 | $439,355 | $559,319 |
| MDX Testing Services | — | $1,317,929 | — | — | — |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Asia and Other | $1,020,556 | $989,225 | — | — | — | — |
| Americas | $1,010,795 | $951,896 | $12,222,650 | $17,544,444 | $8,520,336 | — |
| Europe | $105,584 | $172,369 | $258,355 | $448,847 | $359,509 | $266,701 |
| Asia and Other | — | — | $886,438 | $175,386 | $147,893 | $499,476 |
| United States | — | — | — | — | — | $1,165,320 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Supply Chain | $1,148,816 | $1,208,696 | — | — | — | — |
| Large Scale Dna Production | $612,360 | $584,115 | — | — | — | — |
| Research and Development Services | $375,759 | $311,238 | — | — | — | — |
| Asset Marking | — | $9,441 | $311,809 | $534,594 | $458,409 | $404,888 |
| Clinical Laboratory Service Revenues | — | $1,317,930 | — | — | $4,794,154 | — |
| Clinical Laboratory Testing Services | — | — | — | — | $4,794,154 | $77,550 |
| Clinical Laboratory Testing Services Over Time | — | $1,285,320 | $3,540,456 | $5,127,953 | $562,500 | — |
| Clinical Laboratory Testing Services Point in Time | — | $32,610 | $7,612,975 | $10,398,782 | $4,231,654 | — |
| Diagnostic Kits | — | — | — | — | $1,972,209 | — |
| Large Scale DNA Production | — | $584,115 | $653,015 | — | — | $281,971 |
| Mdx Test Kits and Supplies | — | — | — | $628,286 | $1,972,209 | — |
| Research and Development Services | — | $311,238 | $421,585 | $592,001 | $799,718 | $1,128,511 |
| Supply Chain | — | $1,208,696 | $827,603 | $887,061 | $1,003,248 | $38,577 |
| Asset Marking | — | $9,441 | — | — | — | — |
| Clinical Laboratory Service Revenues | — | $1,330,849 | — | — | — | — |
| Product | — | $1,074,813 | — | — | $3,295,849 | — |
| Service | — | $1,038,677 | — | — | $937,735 | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | -$911,139 | -$2,551,977 | — | — | — |
| Therapeutic DNA Production | -$9,302,642 | -$4,789,272 | — | — | — |
| DNA Tagging and Security Products | — | -$2,551,983 | -$3,550,794 | -$4,652,786 | -$4,823,348 |
| Mdx Testing Services | — | -$1,489,220 | $1,206,652 | -$464,894 | -$274,250 |
| Therapeutic DNA Production | — | -$4,789,268 | -$3,792,871 | -$4,497,699 | -$5,214,221 |
| MDX Testing Services | — | -$1,489,220 | — | — | — |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| DNA Tagging and Security Products | -79.3% | -209.5% | — | — | — |
| Therapeutic DNA Production | -941.5% | -534.9% | — | — | — |
| DNA Tagging and Security Products | — | -209.5% | -309.1% | -295.5% | -278.7% |
| Mdx Testing Services | — | -113% | 10.8% | -2.9% | -4.1% |
| Therapeutic DNA Production | — | -534.9% | -355.7% | -1023.7% | -932.2% |
| MDX Testing Services | — | -113% | — | — | — |